Zobrazeno 1 - 10
of 36
pro vyhledávání: '"G Hantsbarger"'
Autor:
C Karki, P Geransar, G Hantsbarger, K Lee, M Perovic, L Raven, M Sajak-Szczerba, E Sharpe, A Silber, P Tozer
Publikováno v:
Value in Health. 25:S375-S376
Autor:
O Zmora, D C Baumgart, W Faubion, M Ferrante, K Gecse, E Genestin, P Geransar, G Hantsbarger, C Karki, P Tozer, J Panés
Publikováno v:
Journal of Crohn's and Colitis. 16:i536-i537
Background Darvadstrocel (DVS) is a suspension of expanded allogeneic adipose-derived mesenchymal (stromal) stem cells approved for the treatment of complex Crohn’s perianal fistulas (complex CPF). The INSPIRE (EUPAS24267) registry is a European ob
Autor:
C Karki, A Athavale, G Hantsbarger, K Lee, S Milicevic, M Perovic, L Raven, M Sajak-Szczerba, E Sharpe, P Tozer
Publikováno v:
Journal of Crohn's and Colitis. 16:i523-i524
Background Perianal fistulas (PAF) are a common complication associated with Crohn’s disease (CD), and patients with Crohn’s perianal fistulas (CPF) are more likely to experience faecal incontinence (FI) than patients with CD without PAF (non-PAF
Autor:
C Karki, A Athavale, G Hantsbarger, K Lee, S Milicevic, M Perovic, L Raven, M Sajak-Szczerba, V Abilash, P Tozer
Publikováno v:
Journal of Crohn's and Colitis. 16:i472-i473
Background Perianal fistulas (PAF) are a common complication of Crohn’s disease (CD) and patients with Crohn’s perianal fistulas (CPF) experience low health-related quality of life and a higher burden of symptoms than patients with CD without PAF
Autor:
C Karki, E Sharpe, G Hantsbarger, K Lee, M Perovic, L Raven, M Sajak-Szczerba, A Silber, A Yoon, P Tozer
Publikováno v:
Journal of Crohn's and Colitis. 16:i338-i339
Background Perianal fistulas (PAF) are a common complication in Crohn’s disease (CD) and can be associated with an increased burden of illness. A global study was conducted to assess the burden of illness in patients with Crohn’s perianal fistula
Publikováno v:
Journal of Crohn's and Colitis. 15:S092-S093
Background Darvadstrocel (DVS) was approved in 2018 by EMA for treatment of complex perianal fistulas in Crohn’s disease (CPF-CD)1, with evidence on long-term effectiveness still accruing. The objective of this study was to synthesize clinical tria
Publikováno v:
Journal of Crohn's and Colitis. 15:S364-S365
Background Rectovaginal fistulas (RVF) are a difficult to treat perianal complication of Crohn’s disease (CD) with a significant impact on quality of life. Management of RVF includes both medical and surgical interventions. Few studies have assesse
Autor:
P Bossuyt, Edouard Louis, V. Muls, Arnaud Colard, Fazia Mana, V Setakhr, S Vanden Branden, G Van Gassen, A Vijverman, Dimitri Bennett, G Hantsbarger, A Hantson, Severine Vermeire, J L Coenegrachts, A Cremer, A Nakad, F Flamme, Philip Caenepeel, F Baert, D Baert, F D'Heygere, B Strubbe
Publikováno v:
Journal of Crohn's and Colitis. 15:S503-S503
Background Vedolizumab (VDZ) has demonstrated remission in ulcerative colitis (UC) and Crohn’s disease (CD), but its impact on patient (pt) fatigue is not well understood. Herein we report interim fatigue analysis data from a Belgian registry of VD
Autor:
P Bossuyt, V. Muls, D Baert, F Flamme, JC Coche, Fazia Mana, Edouard Louis, S Vanden Branden, K Wijnen, V Setakhr, Severine Vermeire, J L Coenegrachts, A Nakad, B Strubbe, F Baert, E Piters, A Vijverman, P Dolin, F D'Heygere, G Hantsbarger, A Cremer, Philip Caenepeel, Arnaud Colard, A Hantson
Publikováno v:
Journal of Crohn's and Colitis. 14:S501-S502
Background Vedolizumab (VDZ) dose optimisation (DO), by interval shortening from 8-weekly (Q8W) to 4-weekly (Q4W) dosing, is used for patients with secondary loss of response. This report presents outcome data on patients receiving DO in real-world c
Publikováno v:
Journal of Crohn's and Colitis. 12:S032-S034